PENHOET EDWARD

CIK 000119833216 companiesSAN FRANCISCO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001198332

Recent Transactions

50 trades

Disposition to Issuer
IMMUNE DESIGN CORP.
Stock Option (Rt to Buy)
2019-04-02−3,058→ 0 total
Disposition to Issuer
IMMUNE DESIGN CORP.
Stock Option (Rt to Buy)
2019-04-02−10,000→ 0 total
Disposition to Issuer
IMMUNE DESIGN CORP.
Stock Option (Rt to Buy)
2019-04-02−12,500→ 0 total
Disposition to Issuer
IMMUNE DESIGN CORP.
Stock Option (Rt to Buy)
2019-04-02−4,281→ 0 total
Disposition to Issuer
IMMUNE DESIGN CORP.
Stock Option (Rt to Buy)
2019-04-02−12,500→ 0 total
Award
IMMUNE DESIGN CORP.
Stock Option (right to buy)
2019-01-03+12,500→ 12,500 total
Award
IMMUNE DESIGN CORP.
Stock Option (right to buy)
2017-01-04+10,000→ 10,000 total
Award
IMMUNE DESIGN CORP.
Stock Option (right to buy)
2016-01-04+9,300→ 9,300 total
Award
SCYNEXIS INC$SCYX
Stock Option (right to buy)
2015-06-04+8,800→ 8,800 total
Award
IMMUNE DESIGN CORP.
Stock Option (right to buy)
2015-01-07+9,300→ 9,300 total
Award
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2015-01-07+9,000→ 9,000 total
Exercise of In-Money
IMMUNE DESIGN CORP.
Series C Preferred Stock
2014-07-29+305,810→ 305,810 total
Conversion
IMMUNE DESIGN CORP.
Common Stock
2014-07-29+611,620→ 1,877,406 total
Purchase
IMMUNE DESIGN CORP.
Common Stock
2014-07-29$12.00/sh+299,559→ 2,482,775 total
Conversion
IMMUNE DESIGN CORP.
Common Stock
2014-07-29+305,810→ 2,183,216 total
Conversion
IMMUNE DESIGN CORP.
Series B Preferred Stock
2014-07-29−531,843→ 0 total
Conversion
IMMUNE DESIGN CORP.
Series C Preferred Stock
2014-07-29−305,810→ 0 total
Conversion
IMMUNE DESIGN CORP.
Common Stock
2014-07-29+531,843→ 1,265,786 total
Conversion
IMMUNE DESIGN CORP.
Series C Preferred Stock
2014-07-29−611,620→ 0 total
Exercise of In-Money
IMMUNE DESIGN CORP.
Series C Preferred Stock Warrant (right to buy)
2014-07-29−305,810→ 0 total
Conversion
IMMUNE DESIGN CORP.
Series A Preferred Stock
2014-07-29−733,943→ 0 total
Conversion
IMMUNE DESIGN CORP.
Common Stock
2014-07-29+733,943→ 733,943 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Series C Preferred Stock
2014-02-05−158,741→ 0 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05+13,097→ 40,665 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Series C Preferred Stock
2014-02-05−2,363,654→ 0 total
Purchase
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05$11.00/sh+6,940→ 117,760 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Series D Preferred Stock
2014-02-05−89,227→ 0 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05+531,442→ 1,650,117 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Series C Preferred Stock
2014-02-05−58,250→ 0 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05+75,129→ 75,129 total
Purchase
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05$11.00/sh+2,547→ 43,212 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05+35,691→ 110,820 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Series D Preferred Stock
2014-02-05−1,328,604→ 0 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05+27,568→ 27,568 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05+1,118,675→ 1,118,675 total
Conversion
Tvardi Therapeutics, Inc.$TVRD
Series D Preferred Stock
2014-02-05−32,742→ 0 total
Purchase
Tvardi Therapeutics, Inc.$TVRD
Common Stock
2014-02-05$11.00/sh+103,330→ 1,753,447 total
Award
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2014-01-06+2,870→ 2,870 total
Award
CymaBay Therapeutics, Inc.
Stock Appreciation Right
2013-12-23+2,335→ 2,335 total
Award
CymaBay Therapeutics, Inc.
Stock Option (right to buy)
2013-10-31+6,470→ 6,470 total
Award
ChemoCentryx, Inc.
Stock Option (right to buy)
2013-05-23+12,500→ 12,500 total
Sale
Aegerion Pharmaceuticals, Inc.
Common Stock
2012-10-16$18.67/sh−3,160→ 56,190 total
Sale
Aegerion Pharmaceuticals, Inc.
Common Stock
2012-10-16$18.67/sh−128,229→ 2,280,197 total
Sale
Aegerion Pharmaceuticals, Inc.
Common Stock
2012-10-16$18.67/sh−8,611→ 153,131 total
Sale
Aegerion Pharmaceuticals, Inc.
Common Stock
2012-10-15$17.54/sh−1,371→ 59,350 total
Sale
Aegerion Pharmaceuticals, Inc.
Common Stock
2012-10-15$17.54/sh−3,736→ 161,742 total
Sale
Aegerion Pharmaceuticals, Inc.
Common Stock
2012-10-15$17.54/sh−55,626→ 2,408,426 total
Award
ChemoCentryx, Inc.
Stock Option (right to buy)
2012-06-22+12,500→ 12,500 total
Conversion
ChemoCentryx, Inc.
Series C Preferred Stock
2012-02-13−28,723→ 0 total
Conversion
ChemoCentryx, Inc.
Series B Preferred Stock
2012-02-13−2,994,341→ 0 total

Companies

Recent Filings

Address

ONE EMBARCADERO CENTER SUITE 3700

SAN FRANCISCO, CA, 94111

View on SEC.gov